Q COSTA RICA — Costa Rica has set maximum prices for 517 medicines in a move the government expects will produce reductions of close to 30% starting in December.
The price controls cover 68 active ingredients or combinations, meaning the measure applies to multiple brands and presentations sold across the country.
Costa Rica’s Ministerio de Economía, Industria y Comercio (MEIC) — Ministry of Economy, Industry and Commerce — announced the decision as an effort to lower pharmaceutical costs for consumers.
MEIC Minister María del Milagro Solórzano León explained that the intervention addresses the need to protect household spending against the cost of certain medical treatments.
“We are intervening where the market fails to correct itself. It is a temporary, technical, and targeted measure with a clear objective: ensuring people pay less for the medications most critical to their health,” the minister stated.
The new ceilings establish the highest amount pharmacies and other retailers may charge for the medicines included in the regulation. Although the expected reductions are close to 30%, the change experienced by individual consumers will depend on the product and its current retail price.
The policy is due to take effect on December 23, 2026, giving businesses in the pharmaceutical supply chain time to adjust their prices. Once the rules are in force, affected products must be sold at or below the limits established by the government.
According to the MEIC, the measure encompasses 68 active ingredients—or combinations thereof—distributed across 142 pharmaceutical groupings.
These categories include 356 medications identified by their concentration and presentation. When accounting for the various brand-name products available on the domestic market, the total scope extends to 517 products.
Among the active ingredients covered by the decree are atorvastatin, enalapril, levothyroxine, pregabalin, rivaroxaban, rosuvastatin, salbutamol, and valsartan, among others.
These components are used in medications intended for the treatment of various diseases, including cardiovascular conditions, thyroid disorders, and respiratory problems.
How will the price reductions of up to 30% be applied?
A key aspect of the decree is that it does not set a single price for all medicines included in the list, but rather a maximum limit that establishments must observe.
This means a pharmacy may sell a product for less than the set amount but cannot exceed the applicable cap once the regulation takes effect.
According to MEIC estimates, medicines currently sold above the new maximum prices would see an average price reduction of close to 30%.
This percentage does not represent an across-the-board reduction, nor does it guarantee that every one of the 517 products will decrease by exactly that proportion.
To understand how the mechanism works: if a medicine currently sells for ¢10,000 and its new maximum price is set at ¢7,000, the establishment would have to adjust its price to comply with that limit.
The MEIC also expects competition among outlets and brands to trigger further price adjustments for other products within the groups under consideration.
Once the regulation takes effect, MEIC will monitor pharmacies and supply for six months so that the new prices will be mandatory for all economic agents involved in the marketing of the medicines.
For Costa Rican households, the measure could ease the recurring financial burden associated with prescription drugs and other treatments.
Its real effect will become clearer after implementation, when consumers can compare the newly regulated prices with those currently charged at pharmacies.